S
Suzhou Deyun Kangrui Biotechnology
Biotech & Life Sciences · Suzhou Shi, China · Founded 2020
Biophysical analysis of molecular interactions via nanotechnology MoreLess
Dynamic Biosystems is a German company specializing in the development and marketing of biosensors for the analysis of molecular interactions. The company's core technology, switchSENSE®, is a biophysical research tool used to investigate interactions between molecules in real-time. This technology is based on DNA nanolevers attached to gold microelectrodes on a chip surface. By applying an alternating voltage, the DNA nanolevers are made to oscillate, and the system measures changes in fluorescence intensity to provide data on binding kinetics, affinity, and the conformational changes of binding partners. This allows for a detailed, multiparameter characterization of biomolecules from a single measurement.
The company offers a biosensor platform with device series such as the heliX, heliX+, and heliXcyto. The heliX line utilizes the switchSENSE® technology for measuring molecule-molecule interactions. In 2023, the firm introduced Real-Time Interaction Cytometry (RT-IC) with its heliXcyto biosensor, which enables the measurement of molecular interactions directly on the surface of single cells immobilized in micro-cages. This product aims to bridge the gap between traditional biosensor technology and cytometry. The technology serves researchers in basic research, drug discovery, and cell and gene therapy development. The team consists of over 60 life science specialists located in Munich, Germany, and Woburn, MA, in the United States. Suzhou Deyun Kangrui Biotechnology Co., Ltd., established in June 2020, appears to be the Chinese entity related to Dynamic Biosystems' operations, holding numerous patents in the region.
Keywords: molecular interaction analysis, biosensors, DNA nanotechnology, biophysical research, switchSENSE, real-time interaction cytometry, binding kinetics, conformational change analysis, drug discovery tools, gene therapy research, cell analysis, life sciences, microfluidics, fluorescence proximity sensing, biomolecule characterization, protein analysis, ligand binding assays, electro-switchable biosurface, molecular diagnostics, bioanalytics
Company overview
Suzhou Deyun Kangrui Biotechnology company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2020
- Headquarters
- Suzhou Shi, China
- Employees
- —
- Open positions
- None listed
- Dealroom signal
- 19.7
Valuation & funding
Suzhou Deyun Kangrui Biotechnology funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Feb 2023 | $14M | $89M | Guan Ya Investment · Ruihua Capital · Longpan Investment | ↗ |
| SERIES A✓Equity / VC | Nov 2021 | $18M | $72M | Lin Changqing · Rongsheng Venture Capital · Rejing Bio · Hillhouse Capital | — |
| SPINOUT✓Other financing | Jan 2020 | $0 | — | Xiamen University | — |
| SEEDEquity / VC | Jan 2020 | $0 | — | Proxima Ventures | ↗ |
Growth signals
Suzhou Deyun Kangrui Biotechnology website traffic
Latest recorded traffic for Suzhou Deyun Kangrui Biotechnology is 20 monthly website visits.
Comparisons
Suzhou Deyun Kangrui Biotechnology compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 BioSenicFor autoimmune, inflammatory and bone diseases |
Mont-Saint-Guibert, Belgium | Operational | 16 | $9M | $32M |
 RenovacorTransformative Therapies for Cardiovascular Disease |
Narberth, United States | Acquired | |||
 Latch MedicalA new approach to drug and vaccine delivery |
Dublin, Ireland | Operational | |||
 DrugBankAI-powered pharmaceutical knowledge platform for drug development |
Edmonton, Canada | Operational | |||
 PredxBioTissue-Based Decision Intelligence for Oncology |
Bellevue, United States | Operational | |||
 SymbiomicsHigh-performance agricultural biologicals using microbiome and genomic technologies |
Florianópolis, Brazil | Operational | |||
 ZyVersa TherapeuticsA clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs |
Weston, United States | Operational | |||
 Vasa TherapeuticsPrecision medicine for heart failure and healthy aging |
Encinitas, United States | Operational |
Talent graph
Suzhou Deyun Kangrui Biotechnology's talent
Source: Dealroom Talent Intelligence.
Investors
10 investors on Suzhou Deyun Kangrui Biotechnology's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Suzhou Deyun Kangrui Biotechnology has talent and traffic
In the news
Latest news about Suzhou Deyun Kangrui Biotechnology
Recent press, funding announcements, and product moves mentioning Suzhou Deyun Kangrui Biotechnology — open to read from the original sources.
Market sentiment
What the market is saying about Suzhou Deyun Kangrui Biotechnology
An AI-synthesized read of the highest-engagement posts about Suzhou Deyun Kangrui Biotechnology on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Suzhou Deyun Kangrui Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.